Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Direxion Daily LLY Bull 2X Shares (ELIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ELIL (3-star) is a STRONG-BUY. BUY since 68 days. Simulated Profits (54.05%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 54.05% | Avg. Invested days 68 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 15.91 - 26.62 | Updated Date 04/5/2025 |
52 Weeks Range 15.91 - 26.62 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Direxion Daily LLY Bull 2X Shares
Company Overview
History and Background
The Direxion Daily LLY Bull 2X Shares (LLOY) is an exchange-traded fund (ETF) managed by Direxion. It is designed to seek daily investment results that are 200% of the daily performance of Eli Lilly and Company (LLY). Direxion Investments, the fund provider, is known for its leveraged and inverse ETFs. The specific inception date for this ETF would need to be sourced from financial data providers. Its evolution is tied to the performance of its underlying asset, Eli Lilly.
Core Business Areas
- Leveraged ETF Management: The core business is managing exchange-traded funds that aim to provide twice the daily return of a specific underlying asset. In this case, the asset is Eli Lilly and Company's stock.
Leadership and Structure
Direxion Daily LLY Bull 2X Shares is an ETF, not a traditional company with a CEO and board. It is managed by the investment professionals at Direxion Investments, a brand of Crumbie Advisors, LLC.
Top Products and Market Share
Key Offerings
- Competitors: Other leveraged ETFs from providers like ProShares and leveraged ETFs that track indices containing LLY.
- Description: This ETF aims to deliver 200% of the daily performance of Eli Lilly and Company (LLY). It is a short-term investment vehicle, not intended for long-term holding due to potential compounding effects that can lead to divergence from the stated objective over longer periods. Competitors would include other leveraged ETFs tracking individual stocks, or leveraged ETFs tracking broader pharmaceutical indices.
- Market Share Data: Market share for a specific leveraged ETF is difficult to quantify in the traditional sense. Its 'market' is the universe of investors seeking short-term, leveraged exposure to LLY. Its performance and AUM (Assets Under Management) are key indicators of its standing.
- Product Name 1: Direxion Daily LLY Bull 2X Shares (LLOY)
Market Dynamics
Industry Overview
The industry for leveraged ETFs is a niche within the broader ETF market. It caters to sophisticated investors seeking amplified returns and who understand the associated risks, including amplified losses and potential tracking errors over time. The pharmaceutical sector, LLY's underlying industry, is characterized by R&D intensity, regulatory oversight, patent cliffs, and significant growth potential driven by innovation in treatments.
Positioning
LLOY is positioned as a tool for short-term, high-conviction bets on the daily directional movement of Eli Lilly and Company's stock. Its competitive advantage lies in offering amplified daily returns, but this is countered by the inherent risks of leverage and tracking error.
Total Addressable Market (TAM)
The TAM for this specific ETF is the segment of the investment market seeking leveraged, short-term exposure to Eli Lilly and Company. It's a subset of the broader investment market. Direxion's positioning within this TAM is as a provider of specific, daily leveraged exposure, competing with other leveraged products and direct investment in LLY.
Upturn SWOT Analysis
Strengths
- Amplified daily returns potential for short-term speculation.
- Provides access to leveraged exposure to a single, prominent pharmaceutical company (LLY).
- Managed by a recognized provider of leveraged and inverse ETFs (Direxion).
Weaknesses
- High risk of amplified losses due to leverage.
- Potential for significant tracking error over periods longer than one day due to compounding.
- Not suitable for long-term investors.
- High expense ratios compared to broad-market ETFs.
Opportunities
- Periods of high volatility in LLY's stock price can lead to significant daily gains for holders.
- Increased investor appetite for speculative trading strategies.
- New drug approvals or positive clinical trial results for LLY could drive substantial daily price movements.
Threats
- Significant price declines in LLY's stock will result in amplified losses.
- Regulatory changes affecting the pharmaceutical industry.
- Increased competition from other leveraged products or alternative investment strategies.
- Market downturns impacting LLY's stock price.
- Potential for fund closure if AUM becomes too low.
Competitors and Market Share
Key Competitors
- ProShares Ultra Long Eli Lilly (UULT)
Competitive Landscape
LLOY competes with other leveraged ETFs that offer similar exposure to Eli Lilly. Its advantages include its specific 2x leverage and the provider's established presence in the leveraged ETF space. Its disadvantages are the inherent risks of leveraged products and potential tracking differences compared to its competitor.
Growth Trajectory and Initiatives
Historical Growth: The growth of LLOY is directly dependent on the AUM, which is driven by investor demand for leveraged exposure to LLY. Its growth trajectory is not indicative of the company's underlying business but rather market sentiment and trading activity.
Future Projections: Future projections for LLOY are speculative and tied to the anticipated daily volatility and directional movement of Eli Lilly and Company's stock, as well as investor demand for leveraged products.
Recent Initiatives: Direxion periodically reviews its ETF offerings, but specific initiatives for LLOY would be rare unless market conditions or AUM necessitate adjustments.
Summary
Direxion Daily LLY Bull 2X Shares (LLOY) is a highly speculative, short-term investment product designed for amplified daily returns on Eli Lilly and Company's stock. Its strength lies in its leveraged exposure, but it is significantly weakened by the inherent risks of amplified losses and tracking error over time. Opportunities arise from LLY's volatility, while threats include market downturns and regulatory changes. Investors must exercise extreme caution and understand its suitability only for short-term, high-risk trading strategies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Direxion Investments official website (for ETF details and objectives)
- Financial data providers (e.g., Morningstar, Yahoo Finance, Bloomberg) for historical performance and AUM data.
- Industry analysis reports on ETFs and the pharmaceutical sector.
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Leveraged ETFs are complex financial instruments and involve substantial risk of loss. They are not suitable for all investors. Investors should consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The analysis is based on publicly available information and may not be exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Direxion Daily LLY Bull 2X Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-03-26 | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of LLY and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to LLY, consistent with the fund"s investment objective. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.